What You Should Know:
- Medable Inc., a leader in clinical development technology, has announced Medable AI, a suite of generative AI capabilities designed to revolutionize the clinical trial startup process. Medable AI empowers sponsors and clinical research organizations (CROs) to build digital and decentralized trials faster, with greater efficiency and control.
- The launch of Medable AI is part of a broader AI strategy for Medable, with plans to expand AI capabilities across its
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Oxford Cannabinoid Technologies Achieves “Proof of Concept” for AI-Powered Drug Discovery
What You Should Know:
- Oxford Cannabinoid Technologies (OCT) has announced a significant milestone in its drug discovery program: the successful "proof of concept" of its AI-enabled drug discovery asset.
- Developed in collaboration with New York-based tech consultancy Hypatia AI, this cutting-edge tool promises to accelerate OCT's research and development of non-addictive pain medications.
Accelerating Drug Discovery with AI
Hypatia AI's technology acts as an "endlessly
Read More
American Brain Foundation Launches $10M Neuroinflammation Research Initiative
What You Should Know:
- The American Brain Foundation has launched a $10 million cross-disciplinary research initiative that transcends traditional research and philanthropy boundaries by bringing together nonprofit organizations, pharmaceutical and biotech investors, philanthropists, and researchers.
- The initiative will provide funding for research by top neuroscientists to investigate the role of neuroinflammation in a wide range of brain diseases, both neurologic and psychiatric,
Read More
Japan’s National Cancer Center Selects Paradigm for Nationwide Clinical Trial Network
What You Should Know:
- A new cancer treatment and research era is dawning in Japan with the launch of LC-SCRUM-CD (Lung Cancer Genome Screening Project for Individualized Medicine - Clinical Development).
- The nationwide clinical trial network is a collaborative effort between the National Cancer Center (NCC), Precision Medicine Asia Co., Ltd. (PREMIA), and Paradigm Health Inc. (Paradigm).
Building on LC-SCRUM-Asia's Foundation
LC-SCRUM-CD expands upon the existing
Read More
PrognomiQ Raises $34M to Advance Multi-Omics Early Detection Test for Lung Cancer
What You Should Know:
- PrognomiQ, a healthcare company pioneering multi-omics approaches to disease detection, has secured $34M in Series D funding led by Seer, Inc., with participation from a new strategic investor and existing investors including Catalio Capital Management, aMoon, Invus and Bruker.
- The funding brings PrognomiQ’s total funding to more than $135M and will accelerate the development of PrognomiQ's early detection test for lung cancer.
Enhancing Lung
Read More
Evogene and Google Cloud Partner to Develop AI Foundation Model for Drug Discovery
What You Should Know:
- Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene’s ChemPass AI tech-engine to new levels of innovation.
- ChemPass AI is a computational technology platform that directs and accelerates the discovery
Read More
Starget Pharma Secures $5.1M for AI-Powered Targeted Radiotherapy for Cancer
What You Should Know:
- Starget Pharma, an innovative startup specializing in precision cancer diagnostics and targeted radiotherapy, has secured $5.1M in funding from Cancer Focus, a fund established in collaboration with the renowned MD Anderson Cancer Center.
- The investment will support Starget Pharma's upcoming clinical trial for treating advanced metastatic cancers, including sarcomas, neuroendocrine tumors, melanoma, and liver cancer.
Revolutionizing Cancer Treatment
Read More
Accenture Invests in 1910 Genetics to Accelerate AI-Powered Drug Discovery
What You Should Know:
- Accenture has made a strategic investment, through Accenture Ventures, in 1910 Genetics, a biotechnology company revolutionizing drug discovery with its AI-powered platform. Terms of the investment were not disclosed.
- The strategic collaboration will combine Accenture's expertise in scaling AI solutions with 1910 Genetics' innovative technology to help biopharmaceutical companies accelerate drug development, reduce costs, and deliver more effective therapies
Read More
Ready to Change Your Pharmacy Strategy? It’s Time for Analytics, Data, and AI
When you think about pharmacy, the first thing that comes to mind is data, right?
Admittedly, it’s not my first thought either. But for organizations that are chasing after stronger, more integrated strategies to deliver care to patients, a pharmacy data strategy – and pharmacy partnership with analytics platforms – is often the first area of focus to drive change and deliver stronger outcomes.
The idea of “pharmacy” isn’t just in the terms of where a patient picks up their
Read More
H1 Expands Trial Landscape Platform with UK Diversity Data and AI-Powered Site Rescue
What You Should Know:
- H1, a provider of healthcare data and analytics, has announced significant enhancements to its Trial Landscape platform.
- These updates include the integration of diversity data for over 34 million patients in England and the launch of an AI-powered Site Rescue functionality, both designed to accelerate equitable clinical trials and improve research outcomes.
Addressing Diversity in Clinical Trials
Diversity, equity, and inclusion (DEI) are
Read More
